Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gain In Procedures For Newly Insured Under Health Reform May Offset Device Tax, Analyst Says

This article was originally published in The Gray Sheet

Executive Summary

A Wells Fargo analysis on the expected increase in device utilization rates based on expanded insurance coverage due to provisions in the Affordable Care Act will offset the financial impacts of the 2.3 percent device excise tax.

You may also be interested in...

Device Firms Expect Little From Obamacare Insurance Expansion, But Numbers More Complicated

It remains to be seen how many new people end up insured on the Obamacare exchanges, and what the impact will be on device markets. Many executives at implantable companies suggest they will see almost no impact, in part because they get most of their business from Medicare. Government health care statistics, actually suggest a fairly high percentage of under-65-year-old patients get pacemakers, stents, knees and other devices. But there may also be other factors at play.

News In Brief

Bard scores a big win over Gore in a patent dispute. Medtronic announces the launch of a new sheath for its cryoballoon cardiac ablation system. Researchers publish a study on a novel esophageal probe. More news in brief.

Euro Q1 Consumer Health Earnings Preview: Reckitt, Sanofi, Haleon, Bayer

Major Europe-based consumer health players Reckitt, Sanofi, Haleon and Bayer feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q1 2024 results over the coming weeks.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts